Methods and compositions to inhibit symptoms associated with viral upper respiratory tract infections
AssigneeSen-Jam Pharmaceutical LLC
InventorsJacqueline M. Iversen, Thomas A. Dahl
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of reducing or preventing the symptoms associated with the common cold. The method comprises administering to a subject an effective amount of a pharmaceutical composition before presenting with at least one symptom of the common cold. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, salts thereof, and combinations thereof.
Claims14
A method of inhibiting the symptoms associated with viral upper respiratory tract infection, consisting of:
- administering an effective amount of a pharmaceutical composition to a subject at risk of acquiring the viral upper respiratory tract infection, and before viral upper respiratory tract symptoms appear, wherein the active ingredients of the pharmaceutical composition consist of:
- a) a non-steroidal anti-inflammatory drug (NSAID), and/or a salt thereof;
- and
- b) a co-agent selected from the group consisting of:
- fexofenadine, ketotifen, desloratadine, salts thereof, and combinations thereof;
- wherein the pharmaceutical composition does not include a decongestant, and
- wherein the symptoms associated with the viral upper respiratory tract infection are inhibited.
A method of inhibiting the symptoms associated with viral upper respiratory tract infection, consisting of:
- administering to a subject an effective amount of a pharmaceutical composition prior to appearance of a viral upper respiratory tract infection symptom, wherein the active ingredients of the pharmaceutical composition consist of:
- a) about 220 mg to about 880 mg of naproxen sodium, and
- (b) about 60 mg to about 180 mg fexofenadine,
- wherein the pharmaceutical composition does not include a decongestant, and
- wherein the symptoms associated with the viral upper respiratory tract infection are inhibited.
Dependencies are inferred from the claim text.